ClinConnect ClinConnect Logo
Search / Trial NCT03474809

Early Diagnostic of Sepsis and Potential Impact on Antibiotic Management Based on Serial.Pancreatic Stone Protein (PSP) Measured Using the AbioScope.

Launched by ABIONIC SA · Mar 16, 2018

Trial Information

Current as of June 07, 2025

Completed

Keywords

Sepsis, Psp, Abionic

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Adult patients (age ≥ 18 years)
  • 2. Requiring ICU management
  • 3. At high risk of sepsis (septic patients are excluded)
  • 4. Expected ICU stay for more than 4 days
  • 5. Have provided written informed consent or consent is given by the patient's legally designated representative.
  • Exclusion Criteria:
  • 1. Patient expected to die within 48 hours of admission to ICU
  • 2. Patient suffering from or known acute or chronic pancreatitis, pancreatic cancer or admitted after pancreatectomy, but if a patient develops any pancreatic disease during the IUC stay he/she will remain in the study.

About Abionic Sa

Abionic SA is an innovative biotechnology company specializing in the development of rapid diagnostic tests that leverage advanced nanotechnology to improve patient care. Headquartered in Switzerland, Abionic focuses on creating efficient and cost-effective solutions for the early detection of critical health conditions, enabling timely medical interventions. With a commitment to enhancing diagnostic accuracy and accessibility, the company aims to transform the landscape of point-of-care testing, ultimately contributing to better health outcomes worldwide. Through rigorous clinical trials and collaborations, Abionic is dedicated to advancing its pioneering technologies in the healthcare sector.

Locations

Le Mans, , France

Limoges, , France

Pierre Bénite, , France

Tours, , France

Perugia, , Italy

Ravenna, , Italy

Rimini, , Italy

Torino, , Italy

Bern, , Switzerland

Geneva, , Switzerland

Lausanne, , Switzerland

Guildford, , United Kingdom

London, , United Kingdom

London, , United Kingdom

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials